DawnTM is a blood-based test utilizing a simple blood-draw. Our technology requires a small volume of blood that will be analyzed in our CLIA-certified laboratory. We measure glycoproteins using our proprietary technology based on AI. Our AI allows us to discover and measure these never-before characterized biological signals. We measure the patient's biological makeup and decipher clear signals correlated with response outcomes. We currently have data to support DawnTM in pancreatic cancer, lung cancer, melanoma, and are working on other cancers.DAWN'S STORY
In 2017, a young 47-yr old woman was diagnosed with triple negative breast cancer. In her battle with cancer, she endured several therapies. Without a way to select a likely effective therapy, she was only offered IO therapy at a point in time when it was too late for her life to be saved. We named this product as a tribute to her struggle and want to never have a patient not receive a therapy because there is no test to predict its efficacy.
We are in the process of obtaining FDA clearance for DawnTM and will announce when the product will be available.We are working hard with world-renowned partners and medical institutions to bring this test to the clinic and to patients as quickly as possible.
If you are an investigator in IO, or if you are a physician interested in helping us shape the product, we would love to hear from you. If you are a patient we will be announcing our clinical trial in the near future.DAWN@venn.bio